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Two elderly patients with histories of myelodysplastic syndrome and idiopathic thrombocytopenic
purpura both suffered from blurred vision for a long time and asked for cataract surgery. Due to their
extremely low platelet counts, 5000/mL and 6000/mL, respectively, we administrated 12-unit platelet
transfusions each, 2 hours to the surgery. The operations were carried out smoothly, and there were no
bleeding-associated complications during these operative procedures. Both patients were satisﬁed with
their visual improvement at postoperative 1-week follow up with visual acuity of 0.8 and 1.0, respec-
tively, and there was no adverse event reported. From these two cases, we suggested that in patients
with thrombocytopenia, phacoemulsiﬁcation cataract surgery can be performed with preoperative
platelet transfusion, producing favorable results without any bleeding-associated complications.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Thrombocytopenia is a common risk factor for surgery. In
phacoemulsiﬁcation cataract surgery, it can cause serious peri-
ocular or intraocular hemorrhage, and leads to severe complica-
tions. Although topical anesthesia for phacoemulsiﬁcation of
simple cataract with intraocular lens (IOL) implantation was found
to be safe for patients under combined anticoagulant and anti-
platelet therapy,1,2 the risk of intraocular bleeding can still be a
problem in complicated cases. Here, we report two cases of patients
with myelodysplastic syndrome and idiopathic thrombocytopenic
purpura with severe thrombocytopenia that had received platelet
transfusion 2 hours prior to the phacoemulsiﬁcation cataract sur-
gery, and no bleeding-associated complications were encountered
during or after the surgery.y have no ﬁnancial or non-
tter or materials discussed in
logy, Chang Gung Memorial
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2.1. Case 1
This involved a 60-year-old man with refractory cytopenia with
multilineage dysplasia (myelodysplastic syndrome). His myelo-
dysplastic syndrome was diagnosed by bone marrow biopsy 6
months prior to his outpatient department (OPD) visit. In addition,
he was also a hepatitis B carrier. He had no other systemic diseases,
such as diabetes mellitus, or hypertension. He was referred to our
department due to progressive vision blurring in the right eye for 2
months. Best-corrected visual acuity (BCVA) of his right and left
eyes were 0.03 and 0.05, respectively. Slit-lamp examination
revealed mild dense lens in both eyes with N2C1P1-2 under the
grading of Lens Opacities Classiﬁcation System III (LOCS III; Fig. 1A).
An uneventful phacoemulsiﬁcation cataract surgery for his right
eye was scheduled. However, due to preoperative laboratory data
indicating a platelet level of 5000/mL (the normal range is 150,000e
400,000/mL), a 12-unit platelet transfusion was administrated
2 hours prior to the surgery. Later, under topical anesthesia,
phacoemulsiﬁcation and subsequent posterior chamber IOLan. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Case 1, right eye. (A) Preoperative external photo, moderate cataract is noted. (B)
Postoperative Day 1: there is no developed lid ecchymosis, peribulbar hemorrhage,
hyphema or vitreous, retinal or choroidal hemorrhage.
Fig. 2. Case 2, right eye. (A) Preoperative external photo, moderate nuclear sclerosis is
noted. (B) 1-month postoperation: quiet and white conjunctiva without a bleeding
event is noted.
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Suture-less wound closure was applied at the end of the operation.
There was no further ocular or systemic bleeding episode
postoperatively.
After the operation, his postoperative Day-1 follow-up revealed
a favorable wound condition in his right eye with minimal sub-
conjunctival hemorrhage, but without periorbital ecchymosis,
hyphema, or even choroid hemorrhage (Fig. 1B). At his 1-week
follow-up, the BCVA of the right eye revealed an improvement
from 0.03 to 0.8.
2.2. Case 2
This involved a 70-year-old female with steroid refractory se-
vere idiopathic thrombocytopenic purpura, who had undergone
splenectomy 7 years previously, but relapsed 5 years later. After
that, she received steroid treatment, but with poor response.
Therefore, combined treatment with prednisone, imuran, and da-
nazol had been initiated 6 months prior to presentation. She was
also a hepatitis B carrier.
She presented to our outpatient department for progressive
blurring of vision of bilateral eyes. Her initial eye examinations
revealed best visual acuity of 0.07 in her right eye and 0.08 in her
left eye. Slit-lamp examination revealed a dense lens of both eyes
with N3C1P1 under the grading of LOCS III (Fig. 2A). After obser-
vation for 3 months, at the patient’s request, we arranged cataract
surgery for her right eye.
Due to her personal history with steroid refractory thrombo-
cytopenic purpura, we carefully checked her blood cell counts prior
to the operation, which showed a low platelet level of 6000/mL (the
normal range is 150,000e400,000/mL). In order to correct herhemostatic condition, we then administered a 12-unit platelet
transfusion 2 hours prior to the operation. Following that, she un-
derwent phacoemulsiﬁcation cataract surgery with posterior IOL
implantation under topical anesthesia. Prior to the operation, we
made sure that the pupil of her right eye was well dilated and large
enough to prevent intraoperative iris injury. We also applied
suture-less wound closure techniques at the end of the operation.
The operation went smoothly, and there was no severe or uncon-
trolled bleeding noted.
On postoperative Day 1, mild subconjunctival hemorrhage of
her right eye was observed when the wound dressing was
changed (Fig. 2B). Then at her 1-month follow-up clinic, the
subconjunctival hemorrhage in her right eye regressed, and the
BCVA of her right eye improved from 0.07 to 1.0. There was no
bleeding-associated adverse event reported or found on ocular
examination.
Due to the satisfactory outcome of her right eye, 1 month after
the surgery on her right eye, cataract surgery was also performed
on her left eye (Fig. 3A). This time, after discussion with the he-
matologist, we tried to introduce the recently innovated oral
thrombopoietic receptor agonist, eltrombopag, however, the pa-
tient refused it due to economic reasons. Therefore, we again
administrated a platelet transfusion prior to the phacoemulsiﬁca-
tion cataract surgery, and the operation also went smoothly. The 1-
week follow-up showed good wound closure without any sign of
prolonged bleeding (Fig. 3B). The optimal BCVA of 1.0 in this eye
was also achieved by 1 month after the operation from a starting
point of 0.08.
Fig. 3. Case 2, left eye. (A) Preoperative external photo, pharmacologically dilated
pupil, dense nuclear sclerosis with moderate posterior subcortical opacity is noted. (B)
1 week postoperation: mild congested conjunctival vessels without presence of sub-
conjunctival hemorrhage, hyphema, or other bleeding complications.
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Since the early 1990s, phacoemulsiﬁcation with IOL implanta-
tion has become the most popular procedure for cataract surgeons
in most developed countries. Through the introduction of small-
incision phacoemulsiﬁcation, the rate of serious adverse events of
bleeding following cataract surgery has declined over the past few
decades.3 A previous study of patients using antiplatelet or anti-
coagulation medications undergoing cataract surgery, showed no
signiﬁcant impact on discontinuing the antiplatelet and anti-
coagulation therapy.1 Barequet et al2 also reported that there is no
need to stop the systemic anticoagulant and antiplatelet treatment
prior to the phacoemulsiﬁcation cataract surgery using a clear
corneal incision under topical needle-free anesthesia.
However, some bleeding-associated complications may still be
seen, even with this advanced technique. Due to the insufﬁcient
hemostasis, thrombocytopenia has been stated to be a signiﬁcant
risk factor in ocular surgery for perioperative and postoperative
bleedings.4 Therefore, in such cases, sampling blood tests of com-
plete blood cell counts are recommended and further preoperative
hematologic consultation should be arranged.
In the preparation for surgery, there are many anesthesia
methods currently being used. Among the kinds of anesthesia used
for cataract surgery, topical anesthesia is the most commonly
practiced and well-accepted choice. However, the debate between
the use of topical anesthesia and regional anesthesia have not yet
been concluded. In a recent meta-analysis of randomized
controlled trials, Zhao et al5 stated that although topical anesthesiacan be well tolerated in most cataract surgery, alternative anes-
thesia methods are still recommended in speciﬁc patients. How-
ever, with the approach of regional anesthesia by injection,
puncture-related bleeding complications may increase with both
retrobulbar and peribulbar anesthesia, which includes conjunctival
chemosis, sub-conjunctival hemorrhage, periorbital or even retro-
bulbal hematoma.5 Therefore, for patients suffering from throm-
bocytopenia with prolonged coagulation, the risk of these
bleeding-associated complications may pose a threat to the surgi-
cal outcome.
During phacoemulsiﬁcation cataract operations, the processes
that may result in trauma bleeding should be highlighted and
avoided. A stable intraocular pressure and well-formed anterior
chamber during the whole procedure may decrease the possibility
of spontaneous bleeding. However, touching the iris during the
operationmay also increase the risk of subsequent hyphema, which
can lead to an interruption of the operation and lower the success
rate, therefore it should be avoided through careful management.
Suprachoroidal hemorrhage has also been reported as a rare vision-
threatening complication following incisional intraocular surgery,
and its overall incidence ranges from 0.03% to 0.13%.6 The following
concomitant massive hemorrhage and hemorrhage-induced retinal
detachment should also be explained in patients with
thrombocytopenia.
In order to better control the intraoperative bleeding, platelet
transfusion in patients with thrombocytopenia is commonly car-
ried out in some major operations. The normal platelet count range
is around 150,000e400,000/mL, and the threshold of 20,000/mL for
prophylactic transfusion is widely accepted to prevent spontaneous
bleeding.7 For patients undergoing invasive procedures, an optimal
platelet count of >50,000/mL has also been suggested.8 With
regards to platelet transfusion dosage, stable patients without re-
fractory to platelet transfusion can be expected to have an increase
in platelet count of 5000–7000/mL per unit in a 70-kg adult.9 In our
cases, two patients already met the criteria and showed even lower
ﬁgures than the threshold for platelet transfusions for invasive
procedures (platelet counts of 50,000/mL), therefore, 12-unit
platelet transfusions were administrated prior to the surgery to
overcome the patients’ thrombocytopenic status.
However, transfusion of platelet concentrates may also cause
some potential adverse events, such as febrile nonhemolytic trans-
fusion reaction, anaphylactic reaction, transfusion related lung
injury, or infection originating from bacterial contamination.9,10
Although the majority of these reactions are not hazardous and
may subside within 30 minutes after the transfusion, the risk of
following complications shouldbewell informedand close vital sign
surveillance, especially body temperature, may be needed once the
transfusion has started.9 If fever, chills, or even vital sign changes
take place, the transfusion process should be stopped instantly.
However, the recently developed thrombopoietic receptor
agonist, eltrombopag, which was originally proposed to our Case 2
for the surgery of her left eye, may be a possible alternative for
those who have thrombocytopenia and are not susceptible to
transfusion therapy. As a thrombopoietic receptor agonist,
eltrombopag demonstrated its ability to increase platelet count and
reduce the need for platelet transfusion in patients with throm-
bocytopenia and chronic liver disease who were undergoing an
elective invasive procedure.11 Eltrombopag is generally adminis-
trated easily in oral form, and it can raise the platelet count after
75-mg doses once daily for 14 days. Therefore, we could consider
prescribing it for 14 days prior to the cataract surgery if a patient
had experience of adverse transfusion reactions or transfusion-
refractory thrombocytopenia. However, increased risks of
thrombosis-related complications have also been reported, and it
should be used cautiously in patients with a history of thrombotic
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operation, and further surveillance of the long-term beneﬁt is still
required, and it is still not recommended over the use of platelet
transfusion.
In summary, although perioperative bleeding is no longer a
major concern in phacoemulsiﬁcation cataract surgery, with some
studies also reporting good results despite defective platelet func-
tion and insufﬁcient platelet count,1,2,13 some potential complica-
tions may still occur in severely hemostasis-insufﬁcient patients
during cataract surgery. Although we can manage the operation
with topical anesthesia, better techniques to avoid iris injury, better
machines to maintain intraocular pressure during the procedure,
and suture-less wound closure, further intervention may still be
needed to correct a patient’s baseline hemostasis insufﬁciency.
Therefore, preoperative platelet transfusion may provide some
beneﬁts to a patient’s general condition, which could also make the
operation go more smoothly and with a better outcome by
lowering the risk of bleeding-associated complications.
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